Penetrium Bioscience announced on Thursday that it will host a groundbreaking research presentation unveiling the Universal Integrated Therapeutic Mechanism of Penetrium at the Press Center in Seoul’s Jung-gu district at 11:00 a.m. on April 16. This revolutionary discovery comes from the Artificial Intelligence (AI) Bio New Drug Development Team of CN Pharm, the company’s major shareholder.
The presentation, titled, Penetrium: Beyond Disease (Seed) to Environment (Soil), will offer an in-depth look at the integrated therapeutic mechanisms that address cancer, autoimmune diseases, and degenerative brain disorders.
This innovative approach transcends conventional treatment methods that solely target pathogens or cancer cells (Seed). Instead, it aims to fundamentally improve the pathological environment (Soil) where diseases originate and persist.
Through recent collaborations with leading domestic research institutions, the AI Bio New Drug Development Team has cross-validated that Penetrium inhibits the abnormal activation of pathological cell populations at the molecular level, effectively altering the disease microenvironment.
The research team suggests that this groundbreaking microenvironment control mechanism could potentially regulate common underlying causes of major intractable diseases, including cancer, autoimmune disorders, and degenerative brain conditions.
Particularly in the realm of hard-to-treat cancers, the team has gathered compelling scientific evidence showing that Penetrium can dismantle the physical barriers of the tumor microenvironment that shield cancer cells and block immune evasion mechanisms. This breakthrough could potentially overcome the resistance limitations of existing targeted cancer therapies.
Jo Won-dong, Chairman of Penetrium Bioscience, stated that at last year’s 2025 American Association for Cancer Research (AACR) Annual Meeting, it presented animal test results on pseudo-resistance. This upcoming presentation will offer a comprehensive overview of that therapeutic mechanism. He added that it will publicly share objective research data demonstrating how a single substance can suppress the microenvironment of multiple intractable diseases.
Jo emphasized that their participation in the upcoming AACR meeting will not only showcase their research but also potentially catalyze a fundamental shift in the paradigm of the existing targeted cancer drug market.